Literature DB >> 2396604

Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT.

A D'Angelo1, M P Seveso, S V D'Angelo, F Gilardoni, A G Dettori, P Bonini.   

Abstract

Two automatic coagulometers, ACL 810 (Instrumentation Laboratory), a laser-nephelometric centrifugal analyzer, and KoaguLab 40 A (Ortho Diagnostics), an optical automatic coagulometer, were compared with the manual tilt-tube method for the performance of activated partial thromboplastin time (APTT). Seven commercial APTT reagents were used for duplicate determinations in 30 normal controls, 26 patients with liver disease, and 33 patients on full-dose heparin treatment. Clotting times were longer with the manual method than with ACL 810 and, to a lesser extent, with KoaguLab 40 A. Average imprecision of duplicate determinations (coefficient of variation [CV]) was less with ACL 810 (less than 1.5%) than with KoaguLab 40 A (2.9%) and the manual method (2.4%). Differences in slope of the regression curves of clotting times obtained with the coagulometers over the tilt-tube method were observed with all the reagents tested (P less than 0.01). Transformation of clotting times of controls, patients with liver disease, and patients on heparin therapy to APTT ratios did not eliminate the bias resulting from the different reagents (P less than 0.001) and clot-detection methods (P less than 0.001); in controls, significant (P less than 0.001) reagent-method interaction was also observed. The in vitro heparin sensitivity differed with the APTT reagents evaluated and was influenced by the clot-detection method used. Transformation of APTT ratios of anticoagulated patients to apparent plasma heparin levels--as derived from in vitro dose-response curves--effectively eliminated the bias resulting from the different clot-detection methods but had no effect on the bias resulting from the different APTT reagents. In vitro heparin activity curves thus have little, if any, relevance for the ex vivo monitoring of heparin treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2396604     DOI: 10.1093/ajcp/94.3.297

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  Deep Vein Thrombosis.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-06

2.  A sample-to-result system for blood coagulation tests on a microfluidic disk analyzer.

Authors:  Chia-Hui Lin; Cheng-Yuan Liu; Chih-Hsin Shih; Chien-Hsing Lu
Journal:  Biomicrofluidics       Date:  2014-08-22       Impact factor: 2.800

3.  A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits.

Authors:  Pancras C Wong; Earl J Crain; Carol A Watson; William A Schumacher
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

4.  Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects.

Authors:  Pascale Gaussem; M Dubar; B le Bonniec; I Richard-Lordereau; R Jochemsen; M Aiach
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

5.  Mussel-Inspired and Bioclickable Peptide Engineered Surface to Combat Thrombosis and Infection.

Authors:  Xiaohui Mou; Hongbo Zhang; Hua Qiu; Wentai Zhang; Ying Wang; Kaiqin Xiong; Nan Huang; Hélder A Santos; Zhilu Yang
Journal:  Research (Wash D C)       Date:  2022-04-14

Review 6.  Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.

Authors:  Jonathan Douxfils; Anne Tamigniau; Bernard Chatelain; Catherine Goffinet; Jean-Michel Dogné; François Mullier
Journal:  Thromb J       Date:  2014-11-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.